XML 36 R25.htm IDEA: XBRL DOCUMENT v3.26.3
SUBSEQUENT EVENTS
9 Months Ended
Sep. 30, 2026
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS

NOTE 15 - SUBSEQUENT EVENTS:

 

a.Subsequent to September 30, 2026, on November 13, 2026, the Company entered into an underwriting agreement (the “Underwriting Agreement”) with Lake Street Capital Markets, LLC, as representative (the “Representative”) of the several underwriters named therein (collectively, the “Underwriters”), relating to the issuance and sale in an underwritten public offering (the “November 2026 Offering”) of (i) 7,342,308 shares of common stock, and pre-funded warrants to purchase up to 50,350,000 shares of common stock (the “November 2026 Pre-Funded Warrants”), and (ii) accompanying Series L warrants to purchase up to 43,269,231 shares of common stock (or, at the election of the holder, November 2026 Pre-Funded Warrants to purchase up to an equal number of shares of common stock in lieu thereof) (the “Series L Warrants” and, together with the November 2026 Pre-Funded Warrants, the “November 2026 Warrants”), representing 75% of the aggregate number of shares of common stock and November 2026 Pre-Funded Warrants sold in the November 2026 Offering. Each share of common stock is being sold together with an accompanying Series L Warrant at a combined public offering price of $0.65, and each November 2026 Pre-Funded Warrant is being sold together with an accompanying Series L Warrant at a combined public offering price of $0.6499, which equals the combined public offering price per share of common stock and accompanying Series L Warrant, minus $0.0001.

 

The November 2026 Offering closed on November 16, 2026. The gross proceeds from the November 2026 Offering were approximately $37.5 million, and the Company estimates that the gross proceeds from the November 2026 Offering will be approximately $43.1 million if the Representative exercises its option to purchase additional securities in full (as further described below), in each case, prior to deducting underwriting discounts and commissions and estimated offering expenses payable by the Company, and excluding the proceeds, if any, from the exercise of the Warrants.

 

Each November 2026 Pre-Funded Warrant has an exercise price of $0.0001 per share of common stock, is immediately exercisable upon issuance and may be exercised at any time until exercised in full. Each Series L Warrant has an exercise price of $0.65 per share of common stock, is immediately exercisable upon issuance, will expire one year from the date of issuance and may be exercised, at the holder’s election, for pre-funded warrants in lieu of shares of common stock. A holder may not exercise any portion of its November 2026 Warrants to the extent that the holder, together with its affiliates and attribution parties, would beneficially own more than 4.99% (or, at the election of the holder, 9.99%) of the outstanding common stock immediately after exercise.

 

The Company also granted the Representative a 30-day option to purchase up to 8,653,846 additional shares of common stock and/or pre-funded warrants to purchase up to 8,653,846 shares of common stock and/or Series L Warrants to purchase up to 6,490,384 shares of common stock (or pre-funded warrants in lieu thereof) (or any combination thereof) at the applicable public offering price minus underwriting discounts and commissions, representing 15% of the total number of shares of common stock, November 2026 Pre-Funded Warrants and Series L Warrants sold in the November 2026 Offering, solely to cover over-allotment, if any. As of the date hereof, the Representative has not exercised this option.

 

b.Pursuant to the full ratchet anti-dilution adjustment provisions in the certificate of designation for the Company’s Series C preferred stock, following the November 2026 Offering described in Note 15a, the conversion price of the outstanding shares of Series C preferred stock was reduced from $0.7674 to $0.6499 per share, effective as of November 13, 2026, and the number of shares of common stock issuable upon conversion of the Series C preferred stock increased by 2,590 additional shares, to an aggregate of 16,918 shares.